Related references
Note: Only part of the references are listed.Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER plus Breast Cancer
Jun Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
Birong Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
Sharada S. Labadie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan et al.
CELL (2019)
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer
Yunlong Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Johnny Nagasawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Simon J. Johnston et al.
ONCOLOGY AND THERAPY (2018)
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα plus Breast Cancer
Heather E. Burks et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Stapled Peptides with -Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction
Thomas E. Speltz et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Age and Cancer Risk A Potentially Modifiable Relationship
Mary C. White et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2014)
Share Paper
